相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
Lisa Schots et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial
Silje Watterdal Syversen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists
Manasi Agrawal et al.
GASTROENTEROLOGY (2021)
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis
N. Van den Berghe et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
Amit Khatri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review
Mario Regazzi et al.
THERAPEUTIC DRUG MONITORING (2020)
How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Yinuo Pang et al.
CLINICAL PHARMACOKINETICS (2020)
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
Ahmed A. Suleiman et al.
CLINICAL PHARMACOKINETICS (2020)
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study
Shan Pan et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Silje W. Syversen et al.
TRIALS (2020)
Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials
Thomas Kerbusch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Rosa Parisi et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2020)
Omics-Driven Biomarkers of Psoriasis: Recent Insights, Current Challenges, and Future Prospects
Busra Aydin et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2020)
Biologics for the primary care physician: Review and treatment of psoriasis
Eric D. Schadler et al.
DM DISEASE-A-MONTH (2019)
Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks
M. Toro-Montecinos et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Review of safety and efficacy of approved systemic psoriasis therapies
Shivani B. Kaushik et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
Nina Wilkinson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis
Petra Jauslin et al.
CLINICAL PHARMACOKINETICS (2019)
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials
Ahmed A. Suleiman et al.
CLINICAL PHARMACOKINETICS (2019)
Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy
Rani Soenen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Konstantinos Papamichael et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
Amit Khatri et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2019)
Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
Teresa Tsakok et al.
JAMA DERMATOLOGY (2019)
Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
Stine Timmermann et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties
Chiyo K. Imamura
DRUG METABOLISM AND PHARMACOKINETICS (2019)
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Veena A. Thomas et al.
ANTIBODIES (2019)
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Andrew T. Lucas et al.
ANTIBODIES (2019)
Therapeutic drug monitoring of biologics in psoriasis
MeiQi May Liau et al.
BIOLOGICS-TARGETS & THERAPY (2019)
Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
Krisztina Herszenyi et al.
POSTEPY DERMATOLOGII I ALERGOLOGII (2019)
Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
J. M. Carrascosa et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming Liu
PROTEIN & CELL (2018)
In the Clinic Psoriasis
Mark Lebwohl
ANNALS OF INTERNAL MEDICINE (2018)
Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects
Sauzanne Khalilieh et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis
Sauzanne Khalilieh et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Psoriasis: from Pathogenesis to Targeted Therapies
Curdin Conrad et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Psoriasis: implication to disease and therapeutic strategies, with an emphasis on drug delivery approaches
Pooja Todke et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
Emmanuel Chigutsa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis
Zhenling Yao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
Kristian Reich et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis
Chuanpu Hu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
N. M. Mostafa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
Treatment Approaches to Moderate to Severe Psoriasis
Paolo Gisondi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Gerard Bruin et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Critical role of environmental factors in the pathogenesis of psoriasis
Jinrong Zeng et al.
JOURNAL OF DERMATOLOGY (2017)
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients
Chuanpu Hu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment
Agnieszka Bozek et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis
A. Blauvelt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology
E. Dauden et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
E. Molinelli et al.
CURRENT DRUG SAFETY (2016)
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting
S. P. Menting et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
The Immunopathogenesis of Psoriasis
Jaehwan Kim et al.
DERMATOLOGIC CLINICS (2015)
Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
Kristian Reich et al.
EXPERIMENTAL DERMATOLOGY (2015)
Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects
Anthe Zandvliet et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology and Pathogenesis of Psoriasis
Wolf-Henning Boehncke
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis A Step Toward Personalized Treatment
Stef P. Menting et al.
JAMA DERMATOLOGY (2015)
Prevalence of TNF-α Blocker Immunogenicity in Psoriatic Arthritis
Michael Zisapel et al.
JOURNAL OF RHEUMATOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Factors affecting response to biologic treatment in psoriasis
Jacek Karczewski et al.
DERMATOLOGIC THERAPY (2014)
Population Exposure-Response Model to Support Dosing Evaluation of Ixekizumab in Patients With Chronic Plaque Psoriasis
Lai-San Tham et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Population Pharmacokinetics of Brodalumab in Healthy Adults and Adults With Psoriasis From Single and Multiple Dose Studies
Christopher J. Endres et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint
Chuanpu Hu et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Psoriasis
Paola Di Meglio et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
A Semi-Mechanistic Model to Characterize the Pharmacokinetics and Pharmacodynamics of Brodalumab in Healthy Volunteers and Subjects With Psoriasis in a First-in-Human Single Ascending Dose Study
David H. Salinger et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2014)
Biomarkers in psoriasis and psoriatic arthritis
Federica Villanova et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
Hidetoshi Takahashi et al.
JOURNAL OF DERMATOLOGY (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Psoriasis
Gayathri K. Perera et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 7 (2012)
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study
P. Rich et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial
Kim A. Papp et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development
Liang Zhao et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
Alice B. Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Craig Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
J. H. O. Hoffmann et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis
Y.W. Zhu et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma
Hideshi Torii et al.
JOURNAL OF DERMATOLOGY (2011)
Guidelines of care for the management of psoriasis and psoriatic arthritis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Confirmatory analysis for phase III population pharmacokinetics
Chuanpu Hu et al.
PHARMACEUTICAL STATISTICS (2011)
Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
Lidian L. A. Lecluse et al.
ARCHIVES OF DERMATOLOGY (2010)
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Concepts and Lessons for Drug Development
Diane R. Mould et al.
BIODRUGS (2010)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study
Esra Adisen et al.
JOURNAL OF DERMATOLOGY (2010)
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
Akihiko Asahina et al.
JOURNAL OF DERMATOLOGY (2010)
How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review
Phyllis I. Spuls et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
A comprehensive review of biomarkers in psoriasis
R. Rashmi et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-alpha Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
Yaowei Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
An improved approach for confirmatory phase III population pharmacokinetic analysis
Chuanpu Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys
Lu Xu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis
Stephen Tyring et al.
ARCHIVES OF DERMATOLOGY (2007)
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
KB Gordon et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Concomitant administration of bevacizumab, irinotecan, 5-fluorouracil, and leucovorin: Nonclinical safety and pharmacokinetics
J Gaudreault et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease
RG Zinner et al.
LUNG CANCER (2004)
Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
AB Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis
CL Kauffman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Etanercept as monotherapy in patients with psoriasis
CL Leonardi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Psoriatic nails: A prospective clinical study
O Salomon et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2003)
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
LE Friberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure
A Wright et al.
GLYCOBIOLOGY (2000)
分享论文
